These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 7827928

  • 1. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery.
    Drummond M, Aristides M, Davies L, Forbes C.
    Br J Surg; 1994 Dec; 81(12):1742-6. PubMed ID: 7827928
    [Abstract] [Full Text] [Related]

  • 2. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement.
    Hawkins DW, Langley PC, Krueger KP.
    Am J Health Syst Pharm; 1997 May 15; 54(10):1185-90. PubMed ID: 9161627
    [Abstract] [Full Text] [Related]

  • 3. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    Lynd LD, Goeree R, Crowther MA, O'Brien BJ.
    Can J Clin Pharmacol; 2007 May 15; 14(2):e215-26. PubMed ID: 17652767
    [Abstract] [Full Text] [Related]

  • 4. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation.
    Menzin J, Richner R, Huse D, Colditz GA, Oster G.
    Ann Pharmacother; 1994 Feb 15; 28(2):271-5. PubMed ID: 8173149
    [Abstract] [Full Text] [Related]

  • 5. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery.
    Hawkins DW, Langley PC, Krueger KP.
    Clin Ther; 1998 Feb 15; 20(1):182-95. PubMed ID: 9522114
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin.
    Bergqvist D, Lindgren B, Mätzsch T.
    Br J Surg; 1996 Nov 15; 83(11):1548-52. PubMed ID: 9014669
    [Abstract] [Full Text] [Related]

  • 7. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
    Dunn CJ, Goa KL.
    Pharmacoeconomics; 1996 Aug 15; 10(2):179-90. PubMed ID: 10163420
    [Abstract] [Full Text] [Related]

  • 8. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
    Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS.
    Arch Intern Med; 1999 Jun 14; 159(11):1221-8. PubMed ID: 10371230
    [Abstract] [Full Text] [Related]

  • 9. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
    Botteman MF, Caprini J, Stephens JM, Nadipelli V, Bell CF, Pashos CL, Cohen AT.
    Clin Ther; 2002 Nov 14; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
    O'Brien BJ, Anderson DR, Goeree R.
    CMAJ; 1994 Apr 01; 150(7):1083-90. PubMed ID: 8137188
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
    Menzin J, Colditz GA, Regan MM, Richner RE, Oster G.
    Arch Intern Med; 1995 Apr 10; 155(7):757-64. PubMed ID: 7695464
    [Abstract] [Full Text] [Related]

  • 12. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    Lynd LD, Goeree R, Crowther MA, O'Brien BJ.
    Can J Clin Pharmacol; 2007 Apr 10; 14(2):e215-26. PubMed ID: 18000316
    [Abstract] [Full Text] [Related]

  • 13. The cost and benefit of prophylaxis against deep vein thrombosis in elective hip replacement. DVT/PE Prophylaxis Consensus Forum.
    Abdool-Carrim T, Adler H, Becker P, Carides M, Ginsberg J, Golele R, Grobler G, Immelman E, Louwrens H, Lukhele M, Veller M, Watt K, Weber F, Williams E.
    S Afr Med J; 1997 May 10; 87(5):594-600. PubMed ID: 9254816
    [Abstract] [Full Text] [Related]

  • 14. Cost analysis of ardeparin versus enoxaparin for the prophylaxis of deep vein thrombosis after knee arthroplasty.
    Wade WE.
    Clin Ther; 1998 May 10; 20(2):347-51. PubMed ID: 9589825
    [Abstract] [Full Text] [Related]

  • 15. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement.
    Avikainen V, von Bonsdorff H, Partio E, Kaira P, Hakkinen S, Usenius JP, Kaaja R.
    Ann Chir Gynaecol; 1995 May 10; 84(1):85-90. PubMed ID: 7645915
    [Abstract] [Full Text] [Related]

  • 16. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
    Colwell CW, Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD, Comerota AJ, Skoutakis VA.
    J Bone Joint Surg Am; 1994 Jan 10; 76(1):3-14. PubMed ID: 8288662
    [Abstract] [Full Text] [Related]

  • 17. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
    Garcia-Zozaya I.
    J Ky Med Assoc; 1998 Apr 10; 96(4):143-8. PubMed ID: 9577110
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma.
    Devlin JW, Petitta A, Shepard AD, Obeid FN.
    Pharmacotherapy; 1998 Apr 10; 18(6):1335-42. PubMed ID: 9855335
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism.
    Anderson DR, O'Brien BJ.
    Pharmacoeconomics; 1997 Jul 10; 12(1):17-29. PubMed ID: 10169385
    [Abstract] [Full Text] [Related]

  • 20. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P, De Groote K, Annemans L.
    Arch Orthop Trauma Surg; 2004 Oct 10; 124(8):507-17. PubMed ID: 15365714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.